FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre

Acta Oncologica

Volumn 45, Issue 6, 2006, Pages 743-749

  Bjurberg, Maria ^a   Gustavsson, Anita ^a   Ohlsson, Tomas ^a   Brun, Eva ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; CANCER DIAGNOSIS; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; SWEDEN;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SWEDEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748673387     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600644724     Document Type: Review

References (26)

1. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004;5:19-26.
2. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001;91:302-10.
3. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-30.
4. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002;81:20-5.
5. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983-95.
6. Jaffe ES HNL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
7. Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004;15:1699-704.
8. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
9. Hutchings M, Loft A, Hansen MT, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. Blood 2006;107:52-9.
10. Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-4.
11. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29-37.
12. Guay C, Lépine M, Verreault J, Bénard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44:1225-31.
13. Facey K, Bradbury I, Laking A, Payne E. "Ultra rapid review. Positron Emission Tomography (PET) Imaging in Cancer Management". HTA July 2004.
14. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004;52:19-32.
15. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
16. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol, vol 15, No 3 (March), 1997:1123-30.
17. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 1997;314:343-6.
18. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears? Eur J Nucl Med 2000;27:1564-78.
19. Dobert N, Menzel C, Hamscho N, Wordehoff W, Kranert WT, Grunwald F. Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin's and non-Hodgkin's lymphoma. Q J Nucl Med Mol Imaging 2004; vol 48, No 1:33-8.
20. de Hemricourt E, De Boeck K, Hilte F, Abib A, Kockx M, Vandevivere J, et al. Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Mol Imaging Biol 2003;5:15-9.
21. Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999;26:31-8.
22. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11(Suppl 1):147-50.
23. Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001;8:1393-9.
24. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793-800.
25. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-4.
26. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272-8.